RE:RE:S&P Biotech ETF is now up ~3% this year People don't believe it's real. There have been too many twists and turns over the years. They will be proven wrong. Conservative analysis puts Kinlytic alone at $1 for US market and catheter clearance indication only. Europe and Canada will not be far behind which is another $1. Add a buck for the rest of the company and we're at $3. Current price is an absolute steal. Once they start "officially" putting bigger numbers on the board and continue to move Kinlytic along the market will revalue. In my opinion the next Kinlytic milestone will be signing a Contract Manufacturer (CMO). The people with the money behind Sequel don't fool around, do your own due diligence.